- |||||||||| Empliciti (elotuzumab) / AbbVie, BMS
Biomarker, Journal, IO biomarker: NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With Elotuzumab, Lenalidomide Plus Dexamethasone. (Pubmed Central) - Mar 4, 2024 When the cutoff value of CD4/CD8 ratio was 0.792 according to ROC curves, the two-year time to next treatment (TTNT) in the low CD4/CD8 group was significantly longer than that in the high CD4/CD8 group (80.0% vs. 15.0%, p=0.024). The change in NK cells and CD8+ Tregs predicted long-duration ERd and PD, and maintaining low CD4/8 ratio predicted long TTNT, suggesting that these lymphocyte fractions might be biomarkers for a durable therapeutic effect of ERd in myeloma patients.
- |||||||||| dexamethasone / Generic mfg.
Journal, Surgery: A Preservative-Free Approach - Effects on Dry Eye Signs and Symptoms After Cataract Surgery. (Pubmed Central) - Mar 4, 2024 After cataract surgery, patients with mild to moderate dry eyes may experience improved tear film status and reduced symptoms. However, we found no additional beneficial effect on dry eye parameters with treatment with preservative-free dexamethasone, NSAIDs, and lubricants compared to preservative-containing eye drops.
- |||||||||| dexamethasone / Generic mfg.
Journal, Surgery: Efficacy of Bilateral Erector Spinae Block in Patients Undergoing Posterior Spine Fusion Surgeries: A Comparative Randomised Controlled Trial. (Pubmed Central) - Mar 4, 2024 Group C patients received 20 ml of 0.9% sodium chloride (NaCl) on each side, and Group E patients received 20 ml of 0.25% bupivacaine + 4 mg dexamethasone on each side under ultrasound sonography guidance...Results Postoperative VAS was lower in Group E (P < 0.001). There were significant differences in hemodynamic parameters: heart rate (P < 0.045), systolic blood pressure (P < 0.002), diastolic blood pressure (P < 0.003), and mean arterial pressure (P < 0.002) at the time of incision in Group E. Intraoperative opioid requirements at the time of incision (P < 0.036), 60th minutes (P < 0.023), 120th minutes (P < 0.023), and postoperative opioid requirements at the first hour (P < 0.001), sixth hour (P < 0.004), 14th hour (P < 0.025), 20th hour (P < 0.009), and 24th hour (P < 0.025) had lower opioid requirements in Group E than Group C. Conclusion ESP block is a more site-specific dorsal rami block with a better perioperative hemodynamic profile, a part of multimodal analgesia intraoperatively, and excellent postoperative analgesia with fewer postoperative opioid requirements in multilevel spine fusion surgeries.
- |||||||||| Clinical, Journal, Surgery: Ultrasound-guided erector spinae plane block for perioperative analgesia in patients undergoing laparoscopic nephrectomy surgery: A randomized controlled trial. (Pubmed Central) - Mar 4, 2024
There were significant differences in hemodynamic parameters: heart rate (P < 0.045), systolic blood pressure (P < 0.002), diastolic blood pressure (P < 0.003), and mean arterial pressure (P < 0.002) at the time of incision in Group E. Intraoperative opioid requirements at the time of incision (P < 0.036), 60th minutes (P < 0.023), 120th minutes (P < 0.023), and postoperative opioid requirements at the first hour (P < 0.001), sixth hour (P < 0.004), 14th hour (P < 0.025), 20th hour (P < 0.009), and 24th hour (P < 0.025) had lower opioid requirements in Group E than Group C. Conclusion ESP block is a more site-specific dorsal rami block with a better perioperative hemodynamic profile, a part of multimodal analgesia intraoperatively, and excellent postoperative analgesia with fewer postoperative opioid requirements in multilevel spine fusion surgeries. In the ESPB group, a mixture of 10
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Effects of prenatal dexamethasone exposure on adult C57BL/6J mouse metabolism and oxidative stress. (Pubmed Central) - Mar 4, 2024 These data suggest that prenatal dexamethasone exposure in male mice does not alter oxidative stress or metabolism. However, prenatal dexamethasone exposure increased glucocorticoids, cardiac glucose uptake, and pAkt signaling in female heart tissues in adult mice, suggesting there are sex differences in prenatal dexamethasone exposure.
- |||||||||| bleomycin / Generic mfg.
Journal: The Combined Application of Bleomycin and Triamcinolone for Treating Refractory Keloids. (Pubmed Central) - Mar 4, 2024 However, prenatal dexamethasone exposure increased glucocorticoids, cardiac glucose uptake, and pAkt signaling in female heart tissues in adult mice, suggesting there are sex differences in prenatal dexamethasone exposure. The combined use of bleomycin and triamcinolone offers a promising treatment option for individuals who have not responded well to traditional therapies.
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Journal: Analysis of notifications of drug-induced skin ulcers in Spain (Pubmed Central) - Mar 4, 2024 This possibility should not be ruled out when a new skin lesion appears after the administration of new drugs since 25% of the ADRs were unknown at the time of their notification, as were the cases of ulcers associated with i-SGLT2 and vaccines against COVID at the beginning of their commercialization. However, informative health alerts can be generated by continuously notifying suspected ADRs, so we strongly advise reporting any suspected ADRs to the regional pharmacovigilance system.
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka
Enrollment closed, Trial completion date: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 3, 2024 P1/2, N=68, Active, not recruiting, Phase classification: P2b --> P2 Trial completion date: Aug 2027 --> Jan 2027 | Recruiting --> Active, not recruiting
- |||||||||| dexamethasone / Generic mfg.
Journal: Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis. (Pubmed Central) - Mar 3, 2024 Using dexamethasone (DEX) as a model drug, we explored here whether peptide-guided delivery could increase the safety and therapeutic index of glucocorticoids for RA treatment...Last, we found that RXRB expression was significantly elevated in human patient samples, demonstrating the potential of clinical translation. Taken together, we provide a novel, peptide-targeted strategy to improve the therapeutic efficacy and safety of glucocorticoids for RA treatment.
- |||||||||| hydrocortisone / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: ROSES: Role Of Sensitivity to neuroEndocrine Systems in Social Decisions (clinicaltrials.gov) - Mar 2, 2024 P4, N=104, Not yet recruiting, Initiation date: Dec 2023 --> May 2024 Trial completion date: Mar 2025 --> Jul 2025 | Initiation date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Jul 2025
- |||||||||| triamcinolone acetonide / Generic mfg.
Trial completion date, Trial primary completion date: Biological Response to Platelet-rich Plasma and Corticosteroid Injections (clinicaltrials.gov) - Mar 2, 2024 P1/2, N=70, Recruiting, Trial completion date: Dec 2025 --> Aug 2026 Trial completion date: Mar 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| pethidine / Samaritan Pharma
Trial completion date, Trial primary completion date, Surgery: Intrathecal Injection of Pethidine Plus Dexamethasone Versus Bupivacaine Alone (clinicaltrials.gov) - Mar 2, 2024 P2/3, N=46, Active, not recruiting, Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Trial completion date, Combination therapy: MajesTEC-3: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 2, 2024 P3, N=587, Active, not recruiting, Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024 Trial completion date: Oct 2026 --> Dec 2028
- |||||||||| dexamethasone injection / Generic mfg.
Trial completion date, Trial primary completion date: Dexamethasone for Post Traumatic Headache (clinicaltrials.gov) - Mar 2, 2024 P4, N=162, Recruiting, Trial completion date: Apr 2023 --> Jul 2023 Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Jan 2024 --> Sep 2024
- |||||||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 2, 2024 P2, N=7, Active, not recruiting, Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- |||||||||| Kineret (anakinra) / SOBI
Trial completion date: Treatment of Macrophage Activation Syndrome (MAS) With Anakinra (clinicaltrials.gov) - Mar 2, 2024 P1, N=40, Active, not recruiting, Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Trial completion date: Dec 2023 --> Apr 2024
- |||||||||| Rituxan (rituximab) / Roche
Trial completion date: Rituximab (RTX) Therapy in Patients With Active TAO (clinicaltrials.gov) - Mar 2, 2024 P4, N=26, Active, not recruiting, Trial completion date: Dec 2023 --> Apr 2024 Trial completion date: Mar 2024 --> Dec 2024
- |||||||||| budesonide / Generic mfg.
Journal: Effect of WeChat-Based Medication Guidance on Symptoms and Serological Parameters in Children with Mycoplasma Pneumoniae. (Pubmed Central) - Mar 2, 2024 The aim of this study was to assess the effect of microsoft-based medication guidance on the level of symptoms and serological indicators in children receiving budesonide nebulisation combined with terbutaline for the treatment of Mycoplasma pneumoniae pneumoniae (MPP)...After treatment, the levels of forceful spirometry (FVC), 1st-second expiratory volume (FEV1), peak expiratory flow rate (PEF), medication compliance score and family guidance satisfaction rate were higher in the WeChat group than in the conventional group (P < .05). WeChat-based medication guidance can optimize the therapeutic effect of MPP, improve children's medication compliance and satisfaction rate of family guidance, and reduce the occurrence of adverse drug events.
- |||||||||| mometasone furoate / Generic mfg.
Journal: Efficacy of Mometasone Furoate Cream Sodium Alginate Skin Repair Mask in Atopic Dermatitis Treatment. (Pubmed Central) - Mar 2, 2024 By addressing multiple aspects of AD management, including skin barrier repair, moisturization, and inflammation control, the combination of mometasone furoate cream and Alginate Skin Repair Mask provides a more comprehensive treatment approach. This comprehensive approach may contribute to the observed reduction in recurrence rate in the combination group compared to the single group, where only mometasone furoate cream was used.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
Review, Journal: Second-line immunotherapy in new onset refractory status epilepticus. (Pubmed Central) - Mar 2, 2024 There continues to be interest in the utilization of early cytokine measurements to guide treatment selection and response. Prospective studies are necessary to understand the role of early immunomodulation and its associations with epilepsy and functional outcomes.
- |||||||||| dexamethasone / Generic mfg.
Journal: Hyaluronic acid from bleufin tuna by-product: Structural analysis and pharmacological activities. (Pubmed Central) - Mar 2, 2024 In addition, pharmacological evaluation of its anti-inflammatory and analgesic potential, using preclinical models, in comparison with reference drugs (Dexamethasone, diclofenac, and acetylsalicylate of lysine), revealed promising anti-inflammatory activity as well as interesting peripheral and central antinociceptive activity. Therefore, our new hyaluronic acid compound may therefore serve as a potential drug candidate for the treatment of pain sensation and inflammation of various pathological origins.
|